Reach out to us and start your transformative journey!
In the Phase 2 trial published in the New England Journal of Medicine in 2023, investigators assigned participants to placebo or to weekly amounts of 1 mg, 4 mg, 8 mg, or 12 mg over 48 weeks investigational quantities given under supervision
The overall hazard ratio (HR) estimate was 0.59 (95% CI 0.400.79), indicating that tirzepatide resulted from a significant reduction in the risk of MACE-4 compared to the control group [21]
Footnotes Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
However, oral semaglutide exists for diabetes treatment, using special absorption enhancers
GIP improves insulin sensitivity, may influence fat tissue metabolism directly, and appears to amplify the appetite-suppressing effects of GLP-1 in ways researchers are still mapping